Dividends & Buybacks ·
GT Biopharma, Inc. filed Certificates of Elimination to remove all outstanding series of preferred stock from its…
GTBPGT Biopharma, Inc.
GT Biopharma, Inc. filed Certificates of Elimination to remove all outstanding series of preferred stock from its Charter and a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock effective September 8, 2026. The split reduces issued shares from approximately 45.1 million to roughly 1.8 million and lowers authorized capital stock from 265 million to 26.5 million shares. This action follows shareholder approval at the August 14, 2026 annual meeting. GT Biopharma operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.